Affiliation:
1. Rheumatology SHO, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Trust
2. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, UK
Abstract
Abstract
As our understanding of the pathogenesis of SpA improves, focus has turned to the role janus kinase (JAK)-mediated signal transduction and inhibiting its actions as a therapeutic mechanism. Small molecule inhibitors of JAK exist, with variable selectivity for the different JAK isoforms. Less selective JAK inhibitors have variable efficacy and safety profiles, prompting the investigation of selective JAK1 inhibition. In this review, we summarize the current phase 2 and 3 clinical trial data, evaluating the use of JAK1 selective inhibitors in the treatment of SpA, particularly AS and PsA. Selective JAK1 inhibition offers a promising therapeutic approach, however further longer-term trials are needed to fully establish their efficacy and safety at higher doses, and their use in the greater continuum of SpA.
CME:
This supplement is CME Accredited.
To receive a CME certificate of participation, you should:
Read all the papers in the supplement
Register or log in at www.paradigmmc.com/962 to complete and submit the post activity assessment. You must answer 70% of the questions correctly to earn credit. You will have unlimited opportunities to successfully complete the assessment.
You will receive a maximum of 7.0 AMA PRA Category 1 CreditsTM upon successful completion of the assessment.
Funder
National Institute for Health Research
NIHR
Clinician Scientist and Senior Clinical Research Fellow
NIHR Clinician Scientist
Oxford Biomedical Research Centre
Department of Health
Publisher
Oxford University Press (OUP)
Subject
Pharmacology (medical),Rheumatology
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献